Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. reports news on the commercialization and development of photodynamic therapy in dermatology. The company’s core product platform includes Ameluz, an aminolevulinic acid hydrochloride topical gel used with the RhodoLED red-light lamp series, with an established focus on actinic keratoses and clinical programs addressing additional dermatologic conditions.
Recurring updates include financial results, U.S. commercial performance, clinical data for Ameluz PDT, FDA-related label-expansion activity, patent proceedings, and business updates tied to the company’s U.S. product rights, regulatory approvals, intellectual property, and manufacturing rights.
Biofrontera (NASDAQ: BFRI) reported strong growth for the quarter ended June 30, 2026. Q2 net product revenue rose 32.9% year over year to $12.0 million, driven by Ameluz volume growth and pricing, while gross margin expanded to 80% from 71% following the revised Ameluz cost structure after the October 2025 strategic transaction.
Q2 net loss narrowed to $0.6 million or $(0.05) per share, versus a $5.3 million loss a year earlier, and Adjusted EBITDA improved to $(0.2) million from $(5.1) million. For the first half of 2026, revenue increased 25.4% to $22.1 million, gross margin was 80% versus 67%, net loss declined to $5.4 million, and operating cash use fell to $1.7 million from $7.2 million. Cash was $4.7 million and total liabilities $18.1 million at June 30, 2026, with $4.6 million of convertible notes maturing in November 2027 and no bank or term debt.
Biofrontera (NASDAQ: BFRI) announced it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. Management will host a conference call and webcast at 10:00 a.m. Eastern Time the same day to discuss results and provide a business update. Investors can join via U.S./Canada toll-free 1-877-877-1275, international 1-412-858-5202, or through the webcast link, which will be accessible about 20 minutes before the call.
Biofrontera (Nasdaq:BFRI), a biopharmaceutical company focused on photodynamic therapy, will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
Management will deliver a webcast at 11:00 a.m. ET and hold virtual one-on-one investor meetings, with the webcast available for replay.
Biofrontera (NASDAQ:BFRI) reported Q1 2026 revenue of $10.1 million, up ~17% from $8.6 million, driven by ~16% Ameluz unit growth and a price increase. Gross margin rose to about 80%, and operating loss was $4.3 million.
Net loss was $4.8 million ($0.41/share); Adjusted EBITDA improved to $(3.6) million. Cash stood at $6.3 million with minimal operating cash use. The company highlighted positive Phase 3 AK and Phase 2b acne data, FDA sNDA acceptance for sBCC with a September 28, 2026 PDUFA date, and regained Nasdaq bid-price compliance.
Biofrontera (Nasdaq:BFRI) launched its second annual #HatsOnForAK campaign, running May 18–24, 2026, ending on Global Actinic Keratosis Awareness Day. This social media initiative encourages people to wear hats, post photos with dedicated hashtags, and promote awareness of actinic keratosis (AK) and comprehensive sun protection.
Biofrontera (Nasdaq: BFRI) will report first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, May 14, 2026, after U.S. market close. A conference call and webcast are scheduled for May 14, 2026 at 11:00 a.m. ET to discuss results and provide a business update.
The company develops and commercializes photodynamic therapy (PDT) products, including the Ameluz drug-device combination and RhodoLED lamp series, and is conducting clinical trials for non-melanoma skin cancers and moderate-to-severe acne. Webcast access and dial-in details are provided for investors and analysts.
Biofrontera (NASDAQ:BFRI) reported record Q4 2025 revenue of $17.1M (+36% YoY) and a Q4 gross margin of 82.4% versus 58.0% a year earlier. The company posted Q4 net income of $5.6M, cash of $6.4M, and full‑year 2025 revenue of $41.7M.
Key operational moves include purchase of U.S. Ameluz and RhodoLED assets with a reduced earnout (12%–15%), FDA filing acceptance for an sNDA with a PDUFA in September 2026, positive acne and AK trial results, and the Xepi divestiture.
Biofrontera (Nasdaq: BFRI) will report fourth quarter and full year 2025 financial results after U.S. market close on Thursday, March 19, 2026. The company will host a conference call and webcast on March 19, 2026 at 10:00 a.m. ET to discuss results and provide a business update.
Dial-in numbers and a webcast link are provided for investor access.
Biofrontera (Nasdaq: BFRI) reported positive Phase 2b results for Ameluz® PDT in moderate to severe acne vulgaris, with the 3-hour incubation regimen identified as most promising.
In the 3-hour per-protocol cohort, Ameluz achieved a 57.97% reduction in inflammatory lesions vs 36.51% for vehicle; total lesion reductions were 42.7 vs 31.9. Safety was consistent with prior PDT experience. Data will be presented to the FDA in Q3 2026 to discuss next steps.
Biofrontera (Nasdaq: BFRI) announced the U.S. Patent Trial and Appeal Board issued a Final Written Decision on Feb 23, 2026 finding all challenged claims of Sun Pharma’s U.S. Patent No. 11,697,028 unpatentable. Biofrontera had filed Inter Partes Review petitions after Sun Pharma sued for alleged infringement in June 2024.
The decision does not affect Biofrontera’s separate petition on the ’512 patent, which the Patent Office denied review for administrative reasons. Sun Pharma may seek rehearing or appeal to the Federal Circuit.